Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Filings indexed 887 across all filing types
Latest filing 2026-04-28 Quarterly Report
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Quarterly Report 2026
Quarterly Report
2026-04-28 Swedish
Quarterly Report 2026
Quarterly Report
2026-04-28 English
Annual Report 2026
Annual Report
2026-03-31 Swedish
Annual Report 2026
Annual Report
2026-03-31 English
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of Annual General Meeting (AGM) sent to shareholders, containing instructions on participation, postal voting, proxies, and detailed agenda and proposals for resolution. These materials are designed to solicit proxies and inform shareholders ahead of the meeting. This fits the definition of a “Proxy Solicitation & Information Statement” rather than the AGM’s presentation materials or an annual report. Therefore, the correct classification is PSI.
2026-03-27 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice (“Kallelse till årsstämma”) of the Annual General Meeting of Swedish Orphan Biovitrum AB (publ), detailing the date, participation and proxy voting instructions, agenda items, proposals (election of directors, remuneration, incentive programs, etc.). This is an information circular sent to shareholders to solicit votes at the AGM, matching the definition of a Proxy Solicitation & Information Statement.
2026-03-27 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.